{
    "2021-09-03": [
        [
            {
                "time": "",
                "original_text": "中泰证券给予天坛生物增持评级：业绩符合预期，浆站建设、终端覆盖、研发推进带来新增长",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "增持评级",
                        "业绩符合预期",
                        "浆站建设",
                        "终端覆盖",
                        "研发推进",
                        "新增长"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物所属企业获得药物临床试验批件",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "药物临床试验",
                        "批件"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}